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Abstract Despite reduced prevalence of severe forms of
HIV-associated neurocognitive disorders (HAND) on current
antiretroviral therapy (ART) regimens, milder forms of
neurocognitive impairment (NCI) remain prevalent in HIV-
infected populations. These mild forms of HAND consist of
subtypes, probably reflecting distinct, though possibly over-
lapping, pathophysiological mechanisms. Factors associated
with HAND in HIV patients with prolonged viral suppression
on ART include older age, low nadir CD4, active HCV co-
infection, and cardiovascular risk factors, but underlying
mechanisms and their relationship to innate immune activa-
tion, chronic inflammation, and other features of systemic
disease are poorly understood. In this article, we discuss
applications and limitations of plasma inflammatory bio-
markers for studies on HAND in HIV patients on ART and
describe an analysis pipeline to reduce common sources of
noise and increase likelihood of identifying relevant inflam-
matory biomarkers. Clinical covariates and comorbidities that
influence inflammatory biomarkers, such as aging, obesity,
metabolic abnormalities, HCV co-infection, and substance
abuse, are also reviewed. As an example for using this analytic
pipeline, we present an exploratory study of 22 plasma in-
flammatory biomarkers (IFN-α 2b and -γ, 16 cytokines/
chemokines, sIL-2R, sCD14, HA, and YKL-40) in a cohort
of HIV-infected individuals with advanced disease, frequent
HCV co-infection, and viral suppression on ART. The identi-
fication of inflammatory biomarkers associated with HAND
in HIV+ patients on ART may be useful to distinguish be-
tween HAND subtypes with distinct pathophysiology, and is
important for achieving a systems-level understanding of the
biology of these disorders, developing effective therapies, and
evaluating therapeutic outcomes.
Keywords HIV . HCV . HIV-associated neurocognitive
disorders . Innate immune activation . Inflammatory
biomarkers . Interferon-α . IL-6
Introduction
HIV-associated neurocognitive disorders (HAND) range from
asymptomatic neurocognitive impairment (ANI) to minor
neurocognitive disorder (MND) and HIV-associated dementia
(HAD), affecting 20-50 % of HIV-infected individuals despite
viral suppression on combination antiretroviral therapy (ART)
(McArthur and Brew 2010; Sacktor et al. 2002; Tozzi et al.
2005; Letendre et al. 2010; McArthur et al. 2010; Heaton et al.
2011). HIV infects macrophages/microglia in the central ner-
vous system (CNS), and infection and activation of the
monocyte/macrophage system is associated with more severe
forms of HAND (i.e., MND and HAD) in untreated patients
(Gras and Kaul 2010; Ryan et al. 2001; Gartner and Liu 2002;
Gonzalez-Scarano and Martin-Garcia 2005; Kaul et al. 2005;
Ancuta et al. 2008). Less is known about mechanism(s) un-
derlying the mild forms of HAND that are now prevalent in
patients on ARTwith viral suppression in plasma and cerebro-
spinal fluid (CSF). Furthermore, these mild forms of HAND
appear to have subtypes, probably reflecting distinct, though
possibly overlapping, pathophysiological mechanisms. These
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mechanisms are not yet defined, but may include dysregulated
innate immune responses and chronic inflammation associated
with persistently elevated type I and II interferons, ongoing
low-level viral replication, vascular injury, metabolic abnor-
malities, glial cell dysfunction, decreased white matter integ-
rity, and adverse effects of ART drugs (Brew and Letendre
2008; Ances et al. 2009; Everall et al. 2009; Borjabad et al.
2011; Harezlak et al. 2011; Heaton et al. 2011; del Palacio et al.
2012; Gelman et al. 2012a, b; Robertson et al. 2012; Wright
et al. 2012).
Biomarkers are objective and measurable features detected
in biological fluids (i.e. plasma, urine, CSF) that reflect path-
ogenic processes, disease progression, and therapeutic re-
sponses (Naylor 2003; Mayeux 2004). Commonly used in
epidemiological studies to assess risk and in clinical trials as
endpoints, biomarkers can also provide mechanistic insights
into the biology of disease. Although potential biomarkers have
been proposed, there are no specific biomarkers of HAND in
plasma or CSF from HIV patients on suppressive ART and the
accepted standard for HAND diagnosis is based primarily on
standardized screens to assess symptoms and functional impair-
ment, along with neuropsychological testing and excluding other
causes of neurocognitive dysfunction (reviewed in (Schouten
et al. 2011; The Mind Exchange Working Group 2013)).
Despite the success of ART, chronic inflammation con-
tinues to be a hallmark of HIV infection that predicts disease
progression and adverse clinical events (Ortiz and Silvestri
2009; d’Ettorre et al. 2011). Although markers of immune
activation were associated with more severe forms of HAND
in the pre-combination ART era (Brew et al. 1997; Ellis et al.
1997; McArthur et al. 1997; Enting et al. 2000; Ryan et al.
2001; Gartner and Liu 2002; Sacktor et al. 2002), it has been
difficult to identify inflammatory biomarkers associated with
milder forms of HAND in HIV patients with prolonged viral
suppression in the post-combination ART era (The Mind
Exchange Working Group 2013). One explanation for this diffi-
culty is the likely contribution of non-inflammatory mechanisms,
such as cerebrovascular dysfunction, metabolic alterations, or
neurotoxicity of some ART regimens, to some forms of
HAND. Other potential explanations are the lower levels of
immune activation in HIV patients with prolonged viral suppres-
sion on ART and confounding effects of demographic and
disease-related variables (e.g. age, race, gender, nadir CD4
counts, ART regimen, HCV co-infection, heavy smoking, alco-
hol and illicit drug abuse, etc.), which increase noise in the
analytic pipeline and make it more challenging to identify rele-
vant biomarkers. In this article, we discuss potential applications
and limitations of using inflammatory biomarkers to understand
HAND pathophysiology, and describe an analysis pipeline to
reduce sources of noise and increase likelihood of identifying
inflammatory biomarkerswith biological or clinical relevance.As
an example of using this analytic pipeline, we present an explor-
atory study of 22 plasma inflammatory biomarkers in a cohort
of HIV-infected individuals with advanced disease and
suppressed plasma viral load (VL) on ART.
Current state of plasma inflammatory biomarkers
in HAND
In the pre-combination ARTera, disease markers associated with
severe forms of HAND included plasma and CSFHIVRNA and
several inflammatory markers linked to innate immune activation
(e.g., CCL2, IL-6, soluble CD14 [sCD14], neopterin, kynurenine,
quinolinic acid) (Brew et al. 1997; Ellis et al. 1997; McArthur
et al. 1997; Enting et al. 2000; Ryan et al. 2001; Gartner and Liu
2002; Sacktor et al. 2002). In post-combination ARTera cohorts,
however, these associations have not been demonstrated in HIV
patients with prolonged viral suppression on ART. For example,
increased plasma soluble CD14 (sCD14), a monocyte activation
marker, was demonstrated HIV+ patients with advanced disease,
non-suppressed plasma VL on ART, and neurocognitive impair-
ment (NCI); however, plasma sCD14 has not been associated
with NCI in patients with suppressed plasma VL (Ryan et al.
2001; Lyons et al. 2011; Kamat et al. 2012a). Elevated plasma
sCD163, a marker of macrophage activation associated with
cardiovascular disease, is one of the only inflammatory bio-
markers that has been associated with NCI In HIV+ patients with
suppressed plasmaVL on ART (Burdo et al. 2013). Other factors
associated with HAND in HIV patients on suppressive ART are
mainly demographic and disease/comorbidity-related factors, in-
cluding older age (> age 50), low CD4 nadir, active HCV co-
infection, cardiovascular risk factors, and some features of meta-
bolic syndrome (e.g. diabetes and increased waist circumference)
(Ellis et al. 2011; Heaton et al. 2011; Devlin et al. 2012;
McCutchan et al. 2012; Wendelken and Valcour 2012; The
Mind Exchange Working Group 2013; Leeansyah et al. 2013;
Rempel et al. 2013; Sun et al. 2013). Further studies are needed to
identify relevant biomarkers associated with or predictive for
development of HAND in HIV patients with prolonged viral
suppression on current ART regimens.
Potential applications of inflammatory biomarkers
for studies on NeuroAIDS
In HIV patients on suppressive ART, systemic immune acti-
vation is associated with poor clinical outcomes and increased
risk for non-AIDS co-morbidities including cardiovascular,
liver, kidney, and bone disease (Carr 2003; Brown and
Glesby 2012). The causes of persistent immune activation
are poorly understood, and may include low levels of ongoing
HIV replication, microbial translocation, co-infections with
non-HIV pathogens, loss of immunoregulatory cells, persis-
tent elevation of type I and II IFN, and dysregulated cytokine/
chemokine production (Appay and Sauce 2008; Boasso and
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Shearer 2008; d’Ettorre et al. 2011; Sandler and Douek 2012).
Many cellular and soluble immune activation markers have
been used to study relationships between immune activation
and clinical outcomes in patients on ART. T-cell activation is a
strong predictor of morbidity and mortality in untreated HIV
patients (Appay and Sauce 2008; d’Ettorre et al. 2011), but
plasma markers of innate immune activation, including
markers of mononuclear phagocyte activation, are better pre-
dictors of mortality and adverse clinical outcomes such as
cardiovascular disease in HIV patients on ART (Appay and
Sauce 2008; Sandler et al. 2011; Burdo et al. 2013). For
example, elevated plasma sCD14 independently predicts all-
cause mortality in HIV-infected subjects on ART (Sandler
et al. 2011) and the macrophage activation marker sCD163
has been shown to be a predictor of non-calcified coronary
plaques (Aristoteli et al. 2006). Additionally, elevated plasma
IL-6 has been shown to predict age-related comorbidities
including cardiovascular disease and all-cause mortality
(Kuller et al. 2008; Rodger et al. 2009). Further studies are
required to better understand relationships between innate
immune activation and these clinical outcomes.
Despite suppressed plasma viral loads in HIV patients on
ART, a substantial proportion of patients continue to show
evidence of sustained CNS macrophage/microglial activation
and low levels of intrathecal inflammation (Gisolf et al. 2000;
Eden et al. 2007; Schouten et al. 2011). Consistent with these
findings, chronic activation of IFN-α-driven immune re-
sponses has been associated with NCI in HIV patients on
ART in some cohorts (Rempel et al. 2010; Borjabad et al.
2011; Pulliam et al. 2011; Gelman et al. 2012a, b; Rempel
et al. 2013). The identification of a plasma inflammatory bio-
marker panel that may distinguish between HAND subtypes
with different relationships to systemic and/or CNS innate
immune activation in terms of their pathophysiology is impor-
tant for understanding the biology and classification of these
disorders (i.e., caused by inflammatory vs. non-inflammatory
mechanisms) and evaluating therapeutic outcomes.
Practical issues and considerations for inflammatory
biomarker studies in HIV+ cohorts
Strategies to reduce noise in the analysis pipeline
A major challenge in biomarker studies is limiting potential
sources of noise that interfere with the ability to identify valid
biomarkers and increase the probability of identifying false
positives and false negatives. As such, efforts should be made
to reduce sources of noise to optimize study outcomes. Awell-
designed study cohort and analysis workflow can improve
study outcomes by reducing noise in downstream analysis,
which increases the probability of identifying relevant inflam-
matory biomarkers (Fig. 1).
An important first step is selecting well-characterized study
populations. In addition tomatching groups and/or subjects by
age, gender, and race/ethnicity, it is important to consider the
following variables during study design: nadir and current
CD4 cell counts, plasma HIV VL, type of ART regimen,
HCV status (HCV Ab and RNA), alcohol and illicit drug
use/dependence (defined by self-report and/or urine toxicolo-
gy), advanced liver disease, renal failure, and metabolic status
(e.g. extreme obesity defined by very high body-mass index
[BMI], uncontrolled diabetes defined by high hemoglobin
A1c (HbA1c) levels). Several covariates of particular rele-
vance for inflammatory biomarker studies are discussed in
greater detail below. For analysis of neurocognitive status,
education level is another important variable for matching
between groups, or adjustment in multivariate analysis.
Given heterogeneity of current HIV cohorts, it is often not
possible to match groups or subjects by all potentially con-
founding factors. Future cohort studies should be designed to
collect data for these variables in order to achieve a systems-
level understanding of HAND in relation to confounding or
contributing factors, including HCV and other co-infections,
substance abuse, and functions of other relevant organ sys-
tems (e.g., gut, liver, kidney, cardiovascular, and endocrine
system). When matching is not possible, clinical data for
important covariates should be obtained for HIV patients
and controls to characterize the study population. This infor-
mation can then be integrated into downstream analyses
(Fig. 1).
Standardization of sample collection, processing, and stor-
age is also essential to the limit the introduction of potential
sources of noise. Blood samples should be collected using
consistent methods, processed within 30 min of collection to
avoid platelet activation and protein degradation and frozen;
freeze/thaw cycles should be avoided. The age and quality of
samples should be evaluated prior to running immunoassays,
since high variability in storage time or sample quality can
increase noise in immunoassay results. Hemolysis, cell debris,
and platelet contamination should be avoided because they
can interfere with some immunoassays. To minimize batch
effects, immunoassays should be run as consistently as possi-
ble, using the same lot of kits and standards across the study.
For large studies, with samples run on multiple days across
multiple plates, anchor samples (e.g., 4–6 identical samples)
should be included on every plate to register analytes levels
across runs and facilitate batch normalization. Anchor sam-
ples should include representative research specimens from
each subject group (e.g. healthy controls and HIV-infected
subjects) with a range of detectable analyte levels. Batch
effects are common, and normalization can help minimize
effects of inter-run variability.
Data pre-processing is another important step to reduce
noise in data analysis. For analysis of inflammatory bio-
markers, we have found that the ability to identify relevant
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biomarkers is increased by excluding low-quality markers
with poor assay performance and a high proportion of
missing/non-detected values (e.g., >30 % missing values),
analytes known to be affected by confounding technical fac-
tors (e.g., platelet contamination increases RANTES and
platelet-derived growth factor) and analytes with poor inter-
and intra-assay coefficient of variation (e.g., >30 %).
However, when the pattern of missing/non-detected values is
biologically relevant (for example, when most missing/non-
detected values occur in the healthy control group), the data
should be evaluated using non-parametric tests and/or by
transforming the data into a categorical variable. Subjects
identified as extreme outliers (which can reflect technical
factors such as poor sample quality or confounding comor-
bidities such as advanced kidney disease) using unbiased
approaches (e.g., data distribution plots, principal components
analysis (PCA)) during preliminary analyses to evaluate over-
all data architecture, are considered as possible candidates
for exclusion from downstream analyses. However, exclu-
sion of extreme outliers based on unbiased analysis of the
overall dataset should be limited to <5 % of the total study
cohort to avoid outcome bias. Data analysis should use ap-
propriate statistical methods and adjust for multiple-testing.
Bonferroni adjustments for multiple-testing are appropriate
for multiple between-group comparisons to reduce Type 1
errors (false positives), but are too stringent for analysis of
large ‘omics datasets such as untargeted multiplex, metabolo-
mics, and proteomics profiling due to the high rates of Type 2
errors (false negatives). Instead, it is common practice to
control for multiple-testing in multiplex and ‘omics datasets
STUDY DESIGN AND COHORT SELECTION 
• Define inclusion/exclusion criteria (e.g. age cut-offs, current and nadir 
  CD4, HIV viral load, ART regimen, HCV status, other co-infections, illicit  
  drug use, alcohol abuse, BMI, renal failure, confounding medications) 
• Match groups and/or subjects by age, gender, race/ethnicity 
SAMPLE COLLECTION, PROCESSING, AND STORAGE 
• Use consistent type of collection tube (e.g. EDTA or heparin buffer)  
• Process samples within 30 minutes of collection 
• Exclude hemolyzed samples 
• Remove contaminating platelets, cells, cellular debris 
• Store at -80ºC  and avoid freeze/thaw cycles 
IMMUNOASSAYS 
• Consider targeted vs. untargeted approaches 
• Run study samples using kits and standards from the same lot 
• Run equal proportions of study groups in each run 
• Include anchor samples to evaluate % coefficient of variance (CV)  
    and facilitate batch normalization  
DATA  PRE-PROCESSING 
• Impute missing (non-detected) values using lower limit of detection or other  
  methods 
Define acceptability criteria:   
• Exclude analytes by threshold of missing values (e.g. >30 % or >50 % missing values)  
• Exclude analytes affected by technical factors (e.g. platelet contamination increases  
  RANTES and PDGF) 
• Exclude analytes with high inter- and intra-assay % CV  
• Use unbiased approaches (e.g. principal components analysis) to identify subjects      
that are extreme outliers 
• If anchor samples indicate batch effect, perform batch normalization 
• If values show non-normal distributions, consider log2 transformation 
DATA  ANALYSIS 
CLINICAL 
AND LAB 
DATA FOR 
HIV PATIENTS 
AND 
CONTROLS 
• Between-group comparisons using descriptive statistics (e.g. Mann-
Whitney or Kruskal-Wallis tests), adjust p-values for multiple-testing 
• Multivariate analysis to adjust for confounding factors 
• For large cohorts, consider analysis of subgroups or matched strata 
(e.g. by nadir or current CD4, HCV status, type of substance abuse) 
• Validation in an independent cohort 
Fig. 1 Analysis pipeline to
identify plasma inflammatory
biomarkers with biological or
clinical relevance in HIV patients
on ART. Flowchart illustrates
workflow to address issues
important for inflammatory
biomarker study design (yellow
boxes), sample collection and
immunoassays (green boxes), and
data pre-processing and analysis
(blue boxes) to reduce sources of
noise frequently encountered in
inflammatory biomarker studies
in HIV-positive cohorts.
Addressing these issues in study
design, implementation, and data
analysis will increase the chance
of identifying inflammatory
biomarkers with biological or
clinical significance. Similar
workflows were used in prior
studies to identify inflammatory
biomarkers associated with
neurocognitive impairment and
other clinical endpoints in HIV
patients on ART (Lyons et al.
2011; Kamat et al. 2012a, b;
Cassol et al. 2013)
1090 J Neuroimmune Pharmacol (2013) 8:1087–1097
by controlling the false discovery rate (FDR), with acceptable
cut-offs typically below 5 % or 10 %.
Finally, it is important to acknowledge limitations of the
study. When certain variables are not matched or not avail-
able, their potential confounding effects should be discussed.
Ideally, biomarker studies should be performed on large ho-
mogeneous cohorts. However, in reality this is not always
possible. As such, biomarkers should be validated in larger
well-defined independent cohorts. Furthermore, biomarker
associations identified from cross-sectional studies should be
examined in follow-up studies using longitudinal clinical data
to assess predictive value.
Inclusion/exclusion criteria for study design
Factors associated with increased risk of HAND in HIV
patients with viral suppression on ART include older age,
low CD4 nadir, active HCV co-infection, and cardiovascular
risk factors, but the mechanisms underlying HAND and their
relationship to systemic inflammation are poorly understood.
To identify inflammatory biomarkers that may provide mech-
anistic insights into the biology and pathogenesis of HAND,
well-designed biomarker studies should exclude or account
for non-HIV causes of inflammation as discussed below.
Effects of aging on inflammatory biomarkers
Recent studies suggest that HIV may interact with age, par-
ticularly in populations over age 50, increasing the prevalence
of cognitive impairment in older individuals (Goodkin et al.
2001; Justice 2010). However, the strength of this HIV-age
interaction, and age cut-off when it becomes most significant
(i.e. over age 50 vs. over age 60), is still debated (Wendelken
and Valcour 2012). Moreover, HIV-age interactions may be
influenced by a number of clinical covariates, such as duration
of HIV infection, prolonged exposure to certain drugs used in
ART, type of ART regimen, heavy smoking, patterns of sub-
stance abuse (e.g. heavy chronic use of alcohol, cocaine,
methamphetamine, or nitrite inhalants), obesity, and HCV
co-infection. While mechanisms underlying interactions of
HIV infection with aging are poorly understood, they
may relate in part to the known effects of aging on chronic
inflammation. Chronic low-grade inflammation is a common
manifestation of aging, an effect often referred to as
“inflammaging”, and increased circulating levels of inflamma-
tory biomarkers such as IL-6, TNF, C-reactive protein (CRP),
and serum amyloid A, have been detected in elderly compared
to younger subjects, even in the absence of chronic disease
(Shaw et al. 2010; Bruunsgaard and Pedersen 2003;
Franceschi et al. 2007). Accordingly, when designing biomarker
studies, it is important to account for potentially confounding
effects of age on inflammatory biomarker profiles and cognitive
function. As such, study subjects should be matched for age
(within 5 years) and inflammatory biomarkers should be evalu-
ated using approaches that include age as a variable for optimal
study design and analytic workflows.
BMI, metabolic status, and inflammatory biomarkers
Despite the success of ART in reducing HIV-associated mor-
bidity and mortality, long-term treatment is frequently associ-
ated with metabolic abnormalities including dyslipidemia,
lipodystrophy, and insulin resistance (Carr 2003; Brown and
Glesby 2012). Furthermore, similar to recent trends in the
general population, the prevalence of obesity is increasing in
HIV patients on ART (Crum-Cianflone et al. 2010). Many of
these metabolic abnormalities, which include obesity-induced
insulin resistance and type 2 diabetes, are associated with
activation of inflammatory signaling pathways, chronic in-
flammation, and increased risk of inflammatory pathologies
(reviewed in (Hotamisligil 2006; Lumeng and Saltiel 2011)).
Consistent with these findings, in blinded analyses of inflam-
matory biomarkers in heterogenous cohorts, we found that
very high BMI (>40) and high HbA1C (>6.5) were associated
with increased inflammatory biomarker levels in HIV-
negative control subjects. Given these considerations, together
with known inter-relationships between regulation of
metabolism and inflammation, we have used BMI >40 and
HbA1c >6.5 as exclusion criteria when selecting subjects for
inflammatory biomarker studies in smaller HIV+ cohorts when
this data is available. However, given increasing rates of obe-
sity and type 2 diabetes in many control and HIV-infected
populations, a limitation of this approach is that these cut-offs
limit generalizability of findings. As such, in populations with
high rates of obesity and diabetes, inflammatory biomarker
studies can consider alternative approaches, such as excluding
subjects with BMI or HbA1c levels greater than 3 standard
deviations from the mean of the normative population.
Importance of HCVand other co-infections as clinical
covariates
Due to shared methods of transmission, up to 40 % of HIV-
infected individuals are co-infected with HCV (Operskalski and
Kovacs 2011; Taylor et al. 2012). While effective ART has
significantly improved outcomes in co-infected patients, HCV
co-infection can further increase innate immune activation, which
in turn is associatedwith higher risk of neurocognitive impairment
(Ryan et al. 2004; Letendre et al. 2005; Morgello 2005; Morgello
et al. 2005; Parsons et al. 2006; Brew and Letendre 2008; Hinkin
et al. 2008; Martin-Thormeyer and Paul 2009; Cohen et al. 2011;
Devlin et al. 2012; The Mind Exchange Working Group 2013;
Sun et al. 2013). Furthermore, monocyte activation in HIV/HCV
co-infected subjects has been shown to correlate with cognitive
impairment even in those with suppressed plasma HIV RNA
(Rempel et al. 2010; Sun et al. 2013). Given these findings, it is
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important to match, stratify, or exclude by HCV status
(e.g. positive HCV serology and/or HCVRNA) in studies that
seek to identify associations between inflammatory bio-
markers and HIV-related NCI. Other chronic co-infections
such as Hepatitis B, reactivated Cytomegalovirus, and
Tuberculosis, also activate innate immune responses and in-
crease inflammation. As such, occurrence of these co-
infections should be matched, accounted for, or excluded,
for inflammatory biomarker studies in HIV-infected popula-
tions. These approaches will provide a better understanding of
similarities and differences in the biology and phenotypes of
cognitive impairment associated with HIV mono-infection
versus HIV with co-infections, including their relationships
to inflammatory biomarkers and innate immune activation.
Substance abuse can affect inflammatory biomarkers
Substance abuse continues to be closely associated with the
current global HIV epidemic, with an estimated one in three
new HIV infections outside sub-Saharan Africa occurring in
intravenous drug users (Wolfe et al. 2010). Non-injection
recreational drug use is also associated with risk behaviors
linked to HIV transmission. Some forms of drug abuse, par-
ticularly heavy use of cocaine, methamphetamine, and opi-
oids, have been associated with more rapid disease progres-
sion or more severe disease manifestations, including
HIV-associated cognitive impairment (Berman et al. 2006;
Clark et al. 2013). However, the biological basis for these
associations is poorly understood. Substance abuse is associ-
ated with decreased ARTaccess and adherence, but stimulants
and heroin/morphine also have immunomodulatory effects
that can influence inflammation and cognitive function. For
example, cocaine abuse may promote inflammation and HIV
pathogenesis by causing a Th1-Th2 cytokine imbalance and
stimulating IFN-γ responses (Gan et al. 1998; Rios-Olivares
et al. 2006; Kamat et al. 2012b). Likewise, methamphetamine
has been linked to increased neuroinflammation, which may
contribute to its neurotoxic effects (Yamamoto et al. 2010;
Clark et al. 2013). In contrast to these pro-inflammatory
effects of cocaine and methamphetamine, acute and chronic
opioid (i.e., heroin and morphine) administration has immu-
nosuppressive effects, inhibiting humoral and cellular im-
mune responses, natural killer cell activity, cytokine expres-
sion, and phagocytic activity (reviewed in (Vallejo et al.
2004)). Opiate effects on neuroinflammation in HIV infection
appear to be complex (Byrd et al. 2013). Nonetheless, it is
possible to parse deleterious effects of HIVand HIV/HCV co-
infection on cognition from substance abuse, given careful
attention to clinical/demographic characteristics and method-
ological rigor (Byrd et al. 2013). Given immunomodulatory
effects of illicit drugs, information regarding current and
past drug use should be collected when possible, and inte-
grated into the study design and/or data analyses. While data
on self-reported drug use is helpful, urine toxicology data is a
more reliable measure of recent use and should be used when
available to facilitate the evaluation of confounding or ampli-
fying effects of illicit drug use on cognitive impairment.
Evaluating inflammatory biomarkers associated
with HAND: an exploratory analysis in a representative
cohort
To date, there has been limited success in using soluble
markers of immune activation as inflammatory biomarkers
of HAND in HIV patients on suppressive ART, particularly
in patients with mild forms of NCI. This may be due in part to
confounding effects of demographic and disease-related fac-
tors described above, as well as non-inflammatory mecha-
nisms that are likely to underlie some forms of HAND (e.g.,
cerebrovascular, metabolic alterations, neurotoxicity of some
ART drugs, etc.). Previously, we evaluated 17 plasma bio-
markers using the Bio-source 25-plex Human Cytokine Assay
(Invitrogen) in a cohort of HIV patients with advanced disease
and suppressed plasma VL on ART (n =14). We found in-
creased inflammatory biomarkers in plasma and CSF, but
none were associated with NCI (Kamat et al. 2012a).
However, the groups classified by neurocognitive status
(impaired vs. unimpaired) were not well-matched for several
important confounding variables.
To identify inflammatory biomarkers associated with HAND
in a cohort in which groups classified by neurocognitive status
were better matched for confounding variables, we evaluated
22 plasma inflammatory biomarkers (IFN-α 2b and -γ,
16 cytokines/chemokines, sIL-2R, sCD14, HA, and
YKL-40) in 30 HIV+ subjects with CD4 nadir <300,
high frequency of HCV co-infection, and suppressed VL on
ART (<400 plasma HIV RNA copies/ml) and 20 HIV-negative
healthy control subjects. We then examined relationships be-
tween plasma inflammatory biomarkers and neurocognitive
function (assessed by global T scores derived from comprehen-
sive neurocognitive testing at the baseline study visit and after
1 year of follow-up) (Supplemental Methods). The HIV+ sub-
jects were selected to create dichotomous groups (n =15 sub-
jects per group) defined by global T score <40 or ≥40 (corre-
sponding to scores in the impaired or unimpaired range, re-
spectively) matched for age, gender, race/ethnicity, HCV-
serostatus, and class of ART regimen (Supplemental Table 1).
HIV+ subjects were predominantly male (70 %) and African
American (56 %), and at increased risk for HAND due to
advanced disease (median current and nadir CD4 counts of
280 and 60 cells/mL, respectively) and high frequency of HCV
co-infection (70 %). The group with global T scores <40 was
slightly younger (median age 44 vs. 49 years; p =0.06), and had
slightly higher current and nadir CD4 counts, but these differ-
ences were not significant (p =0.25 and 0.41, respectively).
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Although 21 of 22 plasma inflammatory biomarkers were
higher in the total cohort of HIV+ compared to healthy control
subjects (Supplemental Table 2), when HIV+ subjects were
stratified by global T scores at the baseline visit (T score <40
vs. ≥40), no biomarkers distinguished between these groups
classified by current neurocognitive status. IL-6 was slightly
higher in plasma from subjects with NCI (p =0.089), but this
difference was not significant after adjustment for multiple-
testing (Supplemental Table 2).
Examining inter-relationships between these 22 biomarkers
by Pearson correlation analysis, correlation matrix visualization
(Supplemental Fig. 1), and unsupervised clustering on heatmaps
(data not shown), identified a cluster of 7 biomarkers (IFN-α 2b,
IFN-γ, sIL-2R, IL-1RA, IL-1b, IL-6, and IL-12) that correlated
positively in pair-wise comparisons. Previously, we found that
continuous descriptors rather than categorical diagnoses are
better at identifying associations between biomarker levels and
impaired neurocognitive function (Lyons et al. 2011; Kamat
et al. 2012a). We therefore performed Pearson correlation anal-
ysis to examine relationships between global T scores and
inflammatory biomarkers within this correlated cluster. This
approach revealed weak inverse correlations between plasma
IL-6, IFN-α 2b, and sIL-2R and global T scores in unadjusted
univariate models (sIL-2R at p<0.05 and IFN-α 2b and IL-6
p -values 0.05<p <0.1) (Supplemental Fig. 1).
Based on follow-up neurocognitive data (HAND clinical
diagnoses and neurocognitive test scores) available for 23
HIV+ subjects at 6 and 12 months after the baseline study
visit, we then re-classified HIV+ subjects into groups defined
by neurocognitive status 1 year later (see Supplemental
Methods): no NCI/Improved when HAND clinical diagnoses
and neurocognitive test scores indicated unimpaired or im-
proved neurocognitive function (n =7) and stable/worse NCI
when subjects remained stably impaired, were unimpaired at
baseline and became impaired, or were impaired already and
had further decline (n =16; 9 stably impaired and 7 with
decline). The stable/worse NCI group had similar age and
current or nadir CD4 counts (p =.13, .45, and .38, respectively),
but higher frequency of HCV co-infection (80 % vs. 50 %),
compared to the no NCI/improved group. Comparing biomark-
er levels between these groups and healthy controls showed
that IFN-α 2b was the top-ranked biomarker that distinguished
between groups with no or improved NCI versus stable or
worse NCI in univariate models adjusted for multiple compar-
isons by controlling the FDR (Fig. 2 and Supplemental Table 3;
p <0.05 and FDR<5 %). The other biomarkers that distin-
guished these groups were IL-6 and sIL-2R (p <0.05 and
FDR<5 %). The association between these 3 inflammatory
biomarkers and impaired neurocognitive function was detect-
able only when neurocognitive status was characterized using
longitudinal data, probably reflecting more accurate classifica-
tion of neurocognitive status based on longitudinal data and
within-subject trajectories.
Persistent elevation of IFN-α is a major driver of chronic
innate immune activation in HIV infection, and IFN-α sub-
type 2b is the predominant form increased in HIV patient
plasma (Lehmann et al. 2009; Hardy et al. 2013). Prior studies
identified links between chronic type I interferon responses
and HAND in HIV patients on suppressive ART based on
monocyte or brain tissue transcriptome analyses (Rempel
et al. 2010; Borjabad et al. 2011; Pulliam et al. 2011; Gelman
et al. 2012a, b; Rempel et al. 2013). Furthermore, recombinant
IFN-α administration in mouse models is associated with neu-
rotoxicity (Sas et al. 2009; Fritz-French and Tyor 2012). Cohen
et al. (Cohen et al. 2011) and Pederson et al. (Pedersen et al.
2013) previously demonstrated weak associations between
increased plasma IL-6 and impaired neurocognitive function
in HIV patients on ART; one of these cohorts (Cohen et al.
2011) had HIV/HCV co-infection. To our knowledge, plasma
soluble IL-2 receptor, a marker of Tcell activation, has not been
previously linked to HAND. Recombinant IFN-α treatment
increases plasma IL-6, along with IL-1RA, levels in humans
(Tilg et al. 1993; Cotler et al. 2002). Elevated IFN-α 2b, IL-6,
and sIL-2R may be indicative of increased innate immune
activation alongwith its stimulatory effects on T-cell activation.
Accordingly, our exploratory study identified potential links
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Fig. 2 Increased IFN-α 2b, IL-6, and sIL-2R in plasma from HIV+
subjects on ART with stable or progressive neurocognitive impairment
(NCI) versus unimpaired neurocognitive status after 1 year follow-up.
Shown are boxplots for 7 biomarkers identified as highly correlated
features by Pearson correlation analysis (Supplemental Fig. 1). These 7
biomarkers also clustered in heatmaps generated by unsupervised
methods. Box plots show inflammatory biomarker levels in healthy
controls (grey), and HIV subjects with no/improved NCI (orange) or
stable/worse NCI (red) after 1 year follow-up. Medians are represented
by horizontal bars, boxes span the interquartile range (IQR), andwhiskers
extend to extreme data points within 1.5 times the IQR. Outliers are
plotted as open circles and lie outside 1.5 times IQR. P-values were
calculated using the Mann–Whitney U test and adjusting for multiple
comparisons by controlling the false discovery rate (FDR) using p.adjust
in R. (P <0.05 and FDR<5 %) (Supplemental Table 3)
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between markers of innate immune activation and NCI in HIV-
infected and HIV/HCV-coinfected patients on suppressive
ART.
By unsupervised hierarchical clustering, we found that
HIV+ subjects clustered according to levels of plasma
IFN-α 2b and IL-6; one cluster consisted of 11/16 HIV+
subjects with stable impairment or worse NCI 1 year later
with high levels of these biomarkers at the baseline visit, while
the 5 remaining subjects had low levels only slightly above
those of uninfected controls (data not shown). Although the
small sample size limits conclusions that can be drawn, this
preliminary finding, together with previous studies suggesting
increased IFN-α-driven innate immune responses in HAND
pathogenesis and neurotoxicity induced by recombinant
IFN-α administration in mouse models (Sas et al. 2009;
Rempel et al. 2010; Borjabad et al. 2011; Pulliam et al.
2011; Fritz-French and Tyor 2012; Gelman et al. 2012a, b),
suggests these biomarkers may be useful to distinguish be-
tween HAND subtypes that may have different relationships
to systemic inflammation. Further longitudinal studies of larg-
er cohorts of subjects on suppressive ART are needed to
determine relationships of these biomarkers to future risk of
HAND, their utility as biomarkers to distinguish between
HAND subtypes with different underlying mechanisms, and
their relationship to HIV mono-infection versus HIV/HCV
co-infection.
Limitations of this small exploratory study include the
small sample size, which limits the power to detect some
significant associations and precludes multivariate analysis
to evaluate potential confounding effects of low CD4 nadir,
HCV co-infection, or differences in ART regimens. The nar-
row selection criteria used to define the study cohort (CD4
nadir <300) also limits our findings to HIV- or HIV/HCV-
infected individuals with advanced HIV disease. Our cohort
had a high frequency of HCV co-infection (70 %), which may
influence associations between inflammatory biomarkers and
NCI (Cohen et al. 2011; Rempel et al. 2013; Sun et al. 2013).
As such, we cannot exclude the possibility that HCV co-
infection was an important factor driving innate immune
activation and/or NCI. Furthermore, we were unable to clas-
sify our subjects as “active” or “inactive/past” HCV co-
infection due to a lack of available HCV viral load data. A
subset of inflammatory biomarkers in the 27-plex array was
excluded from our analysis because they did not meet accept-
ability criteria (e.g., large numbers of missing values, large
coefficients of variation, etc.). In the current exploratory study,
we used plasma samples to identify inflammatory biomarkers
associated with HAND. Plasma biomarkers mainly reflect
levels of systemic inflammation. Future studies should exam-
ine CSF samples to identify biomarkers of intrathecal inflam-
mation and their relationship to HAND. We included NPI-O
subjects, as many likely exhibit neurocognitive deficits attrib-
utable to HIV, and there is site-to-site variation in assigning
this diagnosis. In past studies, we found that continuous
descriptors of neurocognitive status (global T scores) are more
sensitive indicators of neurocognitive impairment than
categorical diagnoses. However, classification of NCI based
on global T score does not always match HAND clinical diag-
noses. The present study cohort was from NNTC, which spe-
cifically recruits individuals with advanced disease, and
CHARTER, which includes a large population of well-
controlled HIV+ subjects, to represent a diverse popuation of
HIV-infected individuals. As such, the study cohort reflects a
bias of urban cohorts with large populations of advanced disease
or HCV co-infected patients and results cannot be generalized to
all populations. Most of the samples from the NNTC and
CHARTER studies were collected in the mid- to late-2000s
and may not reflect HIV subjects commonly seen in the clinic
today. Further studies are needed to investigate larger, more
recent cohorts with less advanced disease, with active vs. inac-
tive vs. without HCV co-infection, treated with specific ART
regimens, and stratified by age (i.e. < age 50 vs. > = age 50).
Conclusions and future perspectives
In studies to date, no single inflammatory biomarker has
proven valid among independent cohorts for reflecting the
pathobiology of HAND, correlating with its neurocognitive
manifestations, or predicting its future development in HIV
patients with prolonged viral suppression on ART. Based on
the complexity of HAND pathobiology, multifactorial nature
of factors contributing to development of NCI in HIV patients
on suppressive ART (e.g. aging, metabolic status, co-
infections, illicit drug use, etc.), and heterogeneity of current
HIV cohorts (e.g. current and nadir CD4 count, initiation of
ART, and past and current ART regimens), it may not be
possible to identify a single inflammatory biomarker for these
applications. Instead a panel of biomarkers is more likely to
address these important goals in future studies on HAND.
Recently, we identified a plasma inflammatory biomarker
signature consisting of CXCL9, CXCL10, sIL-2R, and
sCD14 that may be useful as a surrogate marker to monitor
immune activation in both viremic and aviremic HIV patients
on ART during disease progression and therapeutic responses
(Kamat et al. 2012b). Likewise, the exploratory analysis in the
present study identified plasma IFN-α 2b, IL-6, and soluble
IL-2 receptor as inflammatory biomarkers that merit further
study to understand their relationship to neurocognitive im-
pairment, innate immune activation, and HCV co-infection in
HIV-infected individuals. Untargeted approaches, such as
multiplex assays, are more likely to identify relevant inflam-
matory biomarkers by screening more candidates, and thereby
increasing the likelihood of identifying unexpected associa-
tions. Moving forward, the integration of inflammatory bio-
markers with data from other high-throughput technologies,
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such as proteomics and metabolomics, will be important next
steps toward the goal of identifying biomarker profiles with
biological, clinical, and prognostic relevance. Using a similar
approach, in a recent study we integrated inflammatory bio-
marker and metabolite profiles with clinical variables and
obtained novel insights into complex relationships between
altered lipid metabolism, hepatic dysfunction, inflammation,
and microbial translocation in HIV patients on PI-based ART
(Cassol et al. 2013). Thus, when integrated with other ‘omics
and clinical data, inflammatory biomarkers are likely to be
important for obtaining a systems-level understanding of
HAND pathogenesis in relation to systemic inflammation
and functional decline of other organ systems in HIV-
infected individuals, and may also be useful for classification
of HAND subtypes and evaluation of new therapies.
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